Pharmaceutical compositions for lipophilic drugs
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/66
A61K-009/48
A61K-009/64
출원번호
UP-0686555
(2007-03-15)
등록번호
US-7799340
(2010-10-11)
발명자
/ 주소
Bhalani, Vinayak T.
Patel, Satishchandra P.
출원인 / 주소
Watson Laboratories, Inc.
대리인 / 주소
Merchant & Gould PC
인용정보
피인용 횟수 :
7인용 특허 :
108
초록▼
Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C6-C12 fatty acid monoglyceride content of at least about 50%, surfact
Stable solutions of lipophilic drugs, such as cyclosporin, forming a polar lipid self-emulsifying drug delivery system. The solutions can include lipophilic drugs, such as cyclosporin, dissolved in a polar lipid, such as having a C6-C12 fatty acid monoglyceride content of at least about 50%, surfactants and triglycerides. The composition forms a fine emulsion on exposure to water. The encapsulated dosage form of this composition needs neither a hydrophilic component nor air-tight blister packaging, and is particularly suitable for oral administration.
대표청구항▼
The invention claimed is: 1. A pharmaceutical composition comprising: a) at least one cyclosporin; b) a surfactant comprising polyoxyethylated castor oil and saturated polyglycolyzed C8-C10 glycerides; and c) a polar lipid component comprising at least one fatty acid partial glyceride comprising at
The invention claimed is: 1. A pharmaceutical composition comprising: a) at least one cyclosporin; b) a surfactant comprising polyoxyethylated castor oil and saturated polyglycolyzed C8-C10 glycerides; and c) a polar lipid component comprising at least one fatty acid partial glyceride comprising at least 50 weight percent monoglycerides of C6-C12 fatty acids; and d) said pharmaceutical composition does not contain a hydrophilic phase containing 1,2-propylene glycol or an ether of formula R1—(—O—(CH2)2)x—OR2, wherein R1 is alkyl or tetrahydrofurfuryl, R2 is alkyl, tetrahydrofurfuryl, or hydrogen, and x is an integer of 1 to 6; and wherein said at least one cyclosporin, said surfactant component, and said polar lipid component are present in effective amounts relative to each other so that the composition, on contact with an aqueous phase, is capable of spontaneously forming a fine emulsion, wherein the weight ratio of said polyoxyethylated castor oil to said saturated polyglycolyzed C8-C10 glycerides is from about 1:1 to 20:1. 2. The pharmaceutical composition according to claim 1, wherein the weight ratio of said polyoxyethylated castor oil to said saturated polyglycolyzed C8-C10 glycerides is from about 5:1 to 9:1. 3. A shelf-stable pharmaceutical composition comprising: a) at least one cyclosporin; b) a surfactant component comprising polyoxyethylated castor oil and saturated polyglycolyzed C8-C10 glycerides; c) a polar lipid component; and d) said pharmaceutical composition does not contain a hydrophilic phase containing 1,2-propylene glycol or an ether of formula R1—(—O—(CH2)2)x—OR2, wherein R1 is alkyl or tetrahydrofurfuryl, R2 is alkyl, tetrahydrofurfuryl, or hydrogen, and x is an integer of 1 to 6; and wherein said at least one cyclosporin, said surfactant component, and said polar lipid component are present in effective amounts relative to each other so that the composition, on contact with an aqueous phase, is capable of spontaneously forming a fine emulsion, wherein the weight ratio of said polyoxyethylated castor oil to said saturated polyglycolyzed C8-C10 glycerides is from about 1:1 to 20:1. 4. The pharmaceutical composition according to claim 3, wherein the weight ratio of said polyoxyethylated castor oil to said saturated polyglycolyzed C8-C10 glycerides is from about 5:1 to 9:1. 5. A pharmaceutical composition comprising: a) at least one cyclosporin; b) a surfactant comprising polyoxyethylated castor oil and saturated polyglycolyzed C8-C10 glycerides; c) a polar lipid component comprising at least one fatty acid partial glyceride comprising at least 50 weight percent monoglycerides of C6-C12 fatty acids; d) at least one triglyceride; and wherein said pharmaceutical composition does not contain a hydrophilic phase containing 1,2-propylene glycol or an ether of formula R1—(—O—(CH2)2)x—OR2, wherein R1 is alkyl or tetrahydrofurfuryl, R2 is alkyl, tetrahydrofurfuryl, or hydrogen, and x is an integer of 1 to 6; and wherein said at least one cyclosporin, said surfactant component, and said polar lipid component are present in effective amounts relative to each other so that the composition, on contact with an aqueous phase, is capable of spontaneously forming a fine emulsion, wherein the weight ratio of said polyoxyethylated castor oil to said saturated polyglycolyzed C8-C10 glycerides is from about 1:1 to 20:1. 6. A pharmaceutical composition comprising: a) about 5 to 20 weight percent of at least one cyclosporin; b) about 30 to 75 weight percent of a surfactant component comprising a polyoxyethylated castor oil; c) about 5 to 50 weight percent of a polar lipid component comprising at least one fatty acid partial glyceride comprising at least 50 weight percent monoglycerides of C6-C12 fatty acids; d) at least one fatty acid triglyceride in an amount not more than about 10 weight percent; wherein said pharmaceutical composition does not contain a hydrophilic phase containing 1,2-propylene glycol or an ether of formula R1—(—O—(CH2)2)x—OR2, wherein R1 is alkyl or tetrahydrofurfuryl, R2 is alkyl, tetrahydrofurfuryl, or hydrogen, and x is an integer of 1 to 6; wherein said at least one cyclosporin, said surfactant component, and said polar lipid component are present in effective amounts relative to each other so that the composition, on contact with an aqueous phase, is capable of spontaneously forming a fine emulsion, wherein said surfactant further comprises a saturated polyglycolyzed C8-C10 glycerides, and wherein the weight ratio of polyoxyethylated castor oil to saturated polyglycolyzed C8-C10 glycerides is about 5:1 to 9:1. 7. A shelf-stable pharmaceutical composition comprising: a) at least one cyclosporin; b) a surfactant component comprising polyoxyethylated castor oil and saturated polyglycolyzed C8-C10 glycerides; c) a polar lipid component; d) a triglyceride component, which is present in an amount not more than about 10 weight percent; and wherein said pharmaceutical composition does not contain a hydrophilic phase containing 1,2-propylene glycol or an ether of formula R1—(—O—(CH2)2)x—OR2, wherein R1 is alkyl or tetrahydrofurfuryl, R2 is alkyl, tetrahydrofurfuryl, or hydrogen, and x is an integer of 1 to 6; and wherein said at least one cyclosporin, said surfactant component, and said polar lipid component are present in effective amounts relative to each other so that the composition, on contact with an aqueous phase, is capable of spontaneously forming a fine emulsion, wherein the weight ratio of said polyoxyethylated castor oil to said saturated polyglycolyzed C8-C10 glycerides is from about 1:1 to 20:1. 8. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition does not contain a hydrophilic component. 9. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition does not contain distinct hydrophilic and lipophilic phases. 10. The pharmaceutical composition according to claim 2, wherein the pharmaceutical composition does not contain a hydrophilic component. 11. The pharmaceutical composition according to claim 2, wherein the pharmaceutical composition does not contain distinct hydrophilic and lipophilic phases. 12. The pharmaceutical composition according to claim 3, wherein the pharmaceutical composition does not contain a hydrophilic component. 13. The pharmaceutical composition according to claim 3, wherein the pharmaceutical composition does not contain distinct hydrophilic and lipophilic phases. 14. The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition does not contain a hydrophilic component. 15. The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition does not contain distinct hydrophilic and lipophilic phases. 16. The pharmaceutical composition according to claim 5, wherein the pharmaceutical composition does not contain a hydrophilic component. 17. The pharmaceutical composition according to claim 5, wherein the pharmaceutical composition does not contain distinct hydrophilic and lipophilic phases. 18. The pharmaceutical composition according to claim 6, wherein the pharmaceutical composition does not contain a hydrophilic component. 19. The pharmaceutical composition according to claim 6, wherein the pharmaceutical composition does not contain distinct hydrophilic and lipophilic phases. 20. The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition does not contain a hydrophilic component. 21. The pharmaceutical composition according to claim 7, wherein the pharmaceutical composition does not contain distinct hydrophilic and lipophilic phases.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (108)
Bachynsky Maria O. (Nutley) Infeld Martin H. (Upper Montclair) Shah Navnit (Clifton) Unowsky Joel (Livingston NJ), Absorption enhancement of antibiotics.
Kelley Vicki E. (Brookline MA) Bennett William M. (Portland OR), Composition having reduced nephrotoxocity comprising a fatty acid containing component and cyclosporine.
Hong Chung Il ; Kim Jung Woo,KRX ; Choi Nam Hee,KRX ; Shin Hee Jong,KRX ; Yang Su Geun,KRX, Cyclosporin-containing microemulsion preconcentrate composition.
Hong Chung Il ; Kim Jung Woo,KRX ; Choi Nam Hee,KRX ; Shin Hee Jong,KRX ; Yang Su Geun,KRX, Cyclosporin-containing microemulsion preconcentrate composition.
Rudnic Edward M. ; McCarty John A. ; Belendiuk ; deceased George W. ; Burnside Beth A. ; McGuinness Charlotte M. ; Belendiuk Krystyna, Emulsified drug delivery system.
Handschumacher Robert E. (97 Great Harbor Rd. Guilford CT 06437) Harding Matthew W. (206 Goffe Ter. New Haven CT 06511) Speicher David W. (91 Fawn Dr. Cheshire CT 06410), Immobilized cyclophilin and methods of using such.
Orbn Erno (Budapest HUX) Balogh Tibor (Budapest HUX) Ila Lajos (Budapest HUX) Ambrus Gbor (Budapest HUX) Jekkel Antnia (Budapest HUX) Elek Sndor (Budapest HUX) Tomori va (Budapest HUX) Elekes Istvn (, Intravenous pharmaceutical composition and process for preparing the same.
Walch Hatto (Laupheim -Baustetten DEX) Fleck Monika (Laupheim DEX) Neuer Klaus (Grossschafhausen DEX), Liquid preparations containing cyclosporin and process for preparing same.
Ebert William R. (Clearwater FL) Hom Foo S. (Clearwater FL) Kindt Warren W. (Clearwater FL), Masticatory soft elastic gelatin capsules and method for the manufacture thereof.
Ausman Robert K. (Long Grove IL) Adams Mark (Milwaukee WI) Caballero Gerado (Milwaukee WI) Hamid Rahim (Wauwatosa WI) Hoffman Norman E. (Wales WI) Quebbeman Edward J. (Brookfield WI) Schulte William , Method for drug administration.
Nussenblatt Robert B. (Bethesda MD) Palestine Alan G. (Potomac MD), Method of treating ocular diseases by periocular administration of cyclosporine A or G.
Pather S. Indiran ; Gupte Sangeeta V. ; Khankari Rajendra K. ; Hontz John ; Robinson Joseph R. ; Eichman Jonathan D. ; Kumbale Ramya, Microemulsions as solid dosage forms for oral administration.
Dumont Francis J. (Rahway NJ) Durette Philippe L. (New Providence NJ) Pessolano Arsenio A. (Colonia NJ) Boger Joshua S. (Westfield NJ) Sigal Nolan H. (Westfield NJ), Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin.
Zenke Gerhard,DEX ; Schuurman Hendrik,CHX ; Haeberlin Barbara,CHX ; Meinzer Armin,DEX, Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin.
Dietl Hans (Eichendorffstr. 33 Bad Aibling DEX D-83043 ), Pharmaceutical preparation containing cyclosporin(s) for oral administration and process for producing same.
Dietl Hans (Eichendorffstr. 33 Bad Aibling DEX D-83043), Pharmaceutical preparation containing cyclosporin(s) for oral administration and process for producing same.
Schmidt Peter C. (Marburg DEX) Stockebrand Bernd (Monchen-Gladbach DEX) Fischer Gerhard (Eberbach DEX), Pharmaceutical preparation with an active substance of low solubility in water and gastric juices.
Popescu Mircea C. (Plainsboro NJ) Tremblay Paul A. (Hamilton NJ) Janoff Andrew S. (Yardley PA) Ostro Marc J. (Princeton NJ) Chan Elaine (Willow Grove PA) Weiner Alan (Lawrenceville NJ), Pharmacological agent-lipid solution preparation.
Eckert Theodor (Muenster DEX) Kemper Fritz H. (Muenster DEX) Wischniewski Martin (Neustadt a. Rbge. DEX) Hempel Reinhard (Hanover DEX), Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparati.
Hahn Lorenz,CHX ; Hauer Birgit,DEX ; Posanski Ulrich,DEX, Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.